53,559 results on '"RADIOSURGERY"'
Search Results
2. Randomized Pilot Study of Radiosurgery for the Treatment of Non-metastatic Prostate Cancer
- Published
- 2024
3. Management of sporadic intracanalicular vestibular schwannomas: A critical review and International Stereotactic Radiosurgery Society (ISRS) practice guidelines.
- Author
-
Balossier, Anne, Sahgal, Arjun, Kotecha, Rupesh, Fariselli, Laura, Gorgulho, Alessandra, Levivier, Marc, Paddick, Ian, Pollock, Bruce, Sheehan, Jason, Suh, John, Yomo, Shoji, Zhang, Zhenwei, Regis, Jean, and Ma, Lijun
- Subjects
conservative surveillance ,intracanalicular ,microsurgical resection ,radiosurgery ,vestibular schwannoma ,Humans ,Neuroma ,Acoustic ,Radiosurgery ,Treatment Outcome ,Retrospective Studies - Abstract
BACKGROUND: The choice of an appropriate strategy for intracanalicular vestibular schwannoma (ICVS) is still debated. We conducted a systematic review and meta-analysis with the aim to compare treatment outcomes amongst management strategies (conservative surveillance (CS), microsurgical resection (MR), or stereotactic radiosurgery (SRS)) aiming to inform guideline recommendations on behalf of the International Stereotactic Radiosurgery Society (ISRS). METHODS: Using PRISMA guidelines, we reviewed manuscripts published between January 1990 and October 2021 referenced in PubMed or Embase. Inclusion criteria were peer-reviewed clinical studies or case series reporting a cohort of ICVS managed with CS, MR, or SRS. Primary outcome measures included tumor control, the need for additional treatment, hearing outcomes, and posttreatment neurological deficits. These were pooled using meta-analytical techniques and compared using meta-regression with random effect. RESULTS: Forty studies were included (2371 patients). The weighted pooled estimates for tumor control were 96% and 65% in SRS and CS series, respectively (P
- Published
- 2024
4. Ki-67 labeling index predicts tumor progression patterns and survival in patients with atypical meningiomas following stereotactic radiosurgery.
- Author
-
Umekawa, Motoyuki, Shinya, Yuki, Hasegawa, Hirotaka, Morshed, Ramin, Katano, Atsuto, Shinozaki-Ushiku, Aya, and Saito, Nobuhito
- Subjects
Atypical meningioma ,Ki-67 labeling index ,Recurrence pattern ,Stereotactic radiosurgery ,Humans ,Meningioma ,Treatment Outcome ,Radiosurgery ,Ki-67 Antigen ,Retrospective Studies ,Meningeal Neoplasms ,Follow-Up Studies - Abstract
PURPOSE: This study investigated whether Ki-67 labeling index (LI) correlated with clinical outcomes after SRS for atypical meningiomas. METHODS: This retrospective study examined 39 patients with atypical meningiomas who underwent SRS over a 10-year study period. Ki-67 LI was categorized into 3 groups: low ( 10%). Local tumor control rates (LCRs), progression-free rates (PFRs), disease-specific survival (DSS) rates, and adverse radiation-induced events (AREs) were evaluated. RESULTS: The median follow-up periods were 26 months. SRS was performed at a median prescription dose of 18 Gy for tumors with a median Ki-67 LI of 9.6%. The 3-year LCRs were 100%, 74%, and 25% in the low, intermediate, and high LI groups, respectively (p = 0.011). The 3-year PFRs were 100%, 40%, and 0% in the low, intermediate, and high LI groups (p = 0.003). The 5-year DSS rates were 100%, 89%, and 50% in the low, intermediate, and high LI groups (p = 0.019). Multivariable Cox proportional hazard analysis showed a significant correlation of high LI with lower LCR (hazard ratio [HR], 3.92; 95% confidence interval [CI] 1.18-13.04, p = 0.026), lower PFR (HR 3.80; 95% CI 1.46-9.88, p = 0.006), and shorter DSS (HR 6.55; 95% CI 1.19-35.95, p = 0.031) compared with intermediate LI. The ARE rates were minimal (8%) in the entire group. CONCLUSION: Patients with high Ki-67 LI showed significantly more tumor progression and tumor-related death. Ki-67 LI might offer valuable predictive insights for the post-SRS management of atypical meningiomas.
- Published
- 2024
5. The University of California San Francisco Brain Metastases Stereotactic Radiosurgery (UCSF-BMSR) MRI Dataset.
- Author
-
Rudie, Jeffrey, Saluja, Rachit, Weiss, David, Nedelec, Pierre, Calabrese, Evan, Colby, John, Laguna, Benjamin, Rauschecker, Andreas, Sugrue, Leo, Hess, Christopher, Mongan, John, Braunstein, Steve, and Villanueva-Meyer, Javier
- Subjects
Artificial Intelligence ,Brain Metastases ,MRI ,Public Datasets ,Humans ,Radiosurgery ,San Francisco ,Brain Neoplasms ,Magnetic Resonance Imaging - Abstract
Supplemental material is available for this article.
- Published
- 2024
6. Genomic alterations associated with postoperative nodular leptomeningeal disease after resection of brain metastases.
- Author
-
Morshed, Ramin, Cummins, Daniel, Nguyen, Minh, Saggi, Satvir, Vasudevan, Harish, Goldschmidt, Ezequiel, Berger, Mitchel, Daras, Mariza, Hervey-Jumper, Shawn, Aghi, Manish, Chang, Edward, McDermott, Mike, Theodosopoulos, Philip, and Braunstein, Steve
- Subjects
CDKN2A ,CDKN2B ,ERBB2 ,brain metastasis ,leptomeningeal disease ,oncology ,surgery ,Humans ,Treatment Outcome ,Retrospective Studies ,Brain Neoplasms ,Radiosurgery ,Genomics - Abstract
OBJECTIVE: The relationship between brain metastasis resection and risk of nodular leptomeningeal disease (nLMD) is unclear. This study examined genomic alterations found in brain metastases with the aim of identifying alterations associated with postoperative nLMD in the context of clinical and treatment factors. METHODS: A retrospective, single-center study was conducted on patients who underwent resection of brain metastases between 2014 and 2022 and had clinical and genomic data available. Postoperative nLMD was the primary endpoint of interest. Targeted next-generation sequencing of > 500 oncogenes was performed in brain metastases. Cox proportional hazards analyses were performed to identify clinical features and genomic alterations associated with nLMD. RESULTS: The cohort comprised 101 patients with tumors originating from multiple cancer types. There were 15 patients with nLMD (14.9% of the cohort) with a median time from surgery to nLMD diagnosis of 8.2 months. Two supervised machine learning algorithms consistently identified CDKN2A/B codeletion and ERBB2 amplification as the top predictors associated with postoperative nLMD across all cancer types. In a multivariate Cox proportional hazards analysis including clinical factors and genomic alterations observed in the cohort, tumor volume (× 10 cm3; HR 1.2, 95% CI 1.01-1.5; p = 0.04), CDKN2A/B codeletion (HR 5.3, 95% CI 1.7-16.9; p = 0.004), and ERBB2 amplification (HR 3.9, 95% CI 1.1-14.4; p = 0.04) were associated with a decreased time to postoperative nLMD. CONCLUSIONS: In addition to increased resected tumor volume, ERBB2 amplification and CDKN2A/B deletion were independently associated with an increased risk of postoperative nLMD across multiple cancer types. Additional work is needed to determine if targeted therapy decreases this risk in the postoperative setting.
- Published
- 2024
7. Adverse radiation effect versus tumor progression following stereotactic radiosurgery for brain metastases: Implications of radiologic uncertainty.
- Author
-
Capaldi, Dante, Raleigh, David, Vasudevan, Harish, Chew, Jessica, Nakamura, Jean, Sneed, Penny, Boreta, Lauren, Villanueva-Meyer, Javier, Ni, Lisa, Morin, Olivier, Theodosopoulos, Philip, Braunstein, Steve, Ziemer, Benjamin, and Salans, Mia
- Subjects
Adverse radiation effect ,Brain metastases ,Stereotactic radiosurgery ,Humans ,Radiosurgery ,Treatment Outcome ,Retrospective Studies ,Uncertainty ,Brain Neoplasms ,Radiation Injuries - Abstract
BACKGROUND: Adverse radiation effect (ARE) following stereotactic radiosurgery (SRS) for brain metastases is challenging to distinguish from tumor progression. This study characterizes the clinical implications of radiologic uncertainty (RU). METHODS: Cases reviewed retrospectively at a single-institutional, multi-disciplinary SRS Tumor Board between 2015-2022 for RU following SRS were identified. Treatment history, diagnostic or therapeutic interventions performed upon RU resolution, and development of neurologic deficits surrounding intervention were obtained from the medical record. Differences in lesion volume and maximum diameter at RU onset versus resolution were compared with paired t-tests. Median time from RU onset to resolution was estimated using the Kaplan-Meier method. Univariate and multivariate associations between clinical characteristics and time to RU resolution were assessed with Cox proportional-hazards regression. RESULTS: Among 128 lesions with RU, 23.5% had undergone ≥ 2 courses of radiation. Median maximum diameter (20 vs. 16 mm, p 6 and > 12 months in 25% and 7% of cases, respectively. Higher total EQD2 prior to RU onset (HR = 0.45, p = 0.03) and use of MR perfusion (HR = 0.56, p = 0.001) correlated with shorter time to resolution; larger volume (HR = 1.05, p = 0.006) portended longer time to resolution. Most lesions (57%) were diagnosed as ARE. Most patients (58%) underwent an intervention upon RU resolution; of these, 38% developed a neurologic deficit surrounding intervention. CONCLUSIONS: RU resolution took > 6 months in > 25% of cases. RU may lead to suboptimal outcomes and symptom burden. Improved characterization of post-SRS RU is needed.
- Published
- 2024
8. A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma
- Author
-
Harris, Jeremy P, Park, Jino, Ku, Eric, Seyedin, Steven, Stitzlein, Russell, Goldin, Amanda, Chen, Wen-Pin, McLaren, Christine, Chen, Allen M, and Chow, Warren
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Vaccine Related ,Immunization ,Radiation Oncology ,Clinical Trials and Supportive Activities ,Cancer ,Minority Health ,Immunotherapy ,Health Disparities ,Clinical Research ,6.1 Pharmaceuticals ,6.5 Radiotherapy and other non-invasive therapies ,Humans ,Antibodies ,Monoclonal ,Humanized ,Immune Checkpoint Inhibitors ,Neoplasms ,Second Primary ,Pilot Projects ,Prospective Studies ,Radiosurgery ,Sarcoma ,immunotherapy ,pembrolizumab ,radiation ,sarcoma ,stereotactic body radiation therapy ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
ObjectivesImmunotherapy with immune checkpoint inhibitors has shown only limited success in the management of metastatic soft tissue sarcoma. Overall response rates (ORR) with single agent pembrolizumab were 18% and median PFS was 18 weeks on the clinical trial SARC028. One strategy to improve the responses to immunotherapy is with stereotactic body radiation therapy (SBRT), which can enhance the antitumor CD8 T cell response through the release of tumor-specific antigens, potentially priming a more diverse class of T cell receptors.MethodsThis is a phase 0, pilot prospective study taking place at a single center with 2 arms. In Arm A, patients are treated with pembrolizumab 400 mg IV infusion on day 1 of a 42-day cycle. Stereotactic body radiation therapy (SBRT) is delivered in 1-5 fractions starting on C1D15-28 and given every other day. In Arm B, patients who have started an immune checkpoint inhibitor within 60 days are treated with SBRT in addition to the current therapy.ResultsIn this study we outline testing the feasibility of adding SBRT to pembrolizumab.ConclusionThe ultimate goal of combination therapy is improved overall response, including tumors not treated with SBRT. This trial can be found registered online: NCT05488366.
- Published
- 2024
9. Vein of galen malformations: for patients and caregivers.
- Author
-
Aydin, Serhat, Darko, Kwadwo, Detchou, Donald, and Barrie, Umaru
- Abstract
Vein of Galen malformations (VOGMs), also known as Vein of Galen Aneurysmal Malformations (VGAMs), are rare and complex cerebrovascular anomalies that pose significant diagnostic and therapeutic challenges. These malformations result from abnormal arteriovenous shunts during embryonic development, leading to a range of severe clinical manifestations, including high-output cardiac failure and hydrocephalus. Advances in prenatal imaging, particularly fetal MRI, have improved early detection, allowing for timely intervention. Endovascular techniques, especially transarterial embolization, have become the primary treatment modality, often preferred over surgical approaches due to their effectiveness and lower risk. However, challenges remain, particularly in managing these malformations in neonates and infants, where the risk of complications is high. Gamma Knife radiosurgery offers a non-invasive alternative for select cases, though its effects are gradual and may carry delayed risks. Despite advancements, the management of VOGMs continues to require a multidisciplinary approach, with ongoing research focused on improving outcomes through a better understanding of the genetic and molecular underpinnings of the disease. Future directions include the integration of genetic studies into clinical practice and the refinement of treatment strategies to optimize outcomes for this complex condition. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. The Role of Surgery in Metastatic Renal Cell Carcinoma in 2024.
- Author
-
Leung, David KW, Ko, Ivan CH, Siu, Brian WH, Wong, Chris HM, Yuen, Steffi KK, Ng, Chi Fai, and Teoh, Jeremy YC
- Subjects
- *
PATIENT selection , *RADIOTHERAPY , *PATIENT safety , *DISEASE management , *IMMUNOTHERAPY , *NEPHRECTOMY , *RADIOSURGERY , *METASTASIS , *RENAL cell carcinoma , *INDIVIDUALIZED medicine , *HEALTH care teams - Abstract
Renal cell carcinoma (RCC) is the most common solid tumour of the kidney and accounts for 3% of all cancers. While immune checkpoint inhibitor (ICI)-based combination therapies have emerged as the first-line treatment for metastatic renal cell carcinoma (mRCC), the role of surgery has become more controversial. This review summarizes the evidence, current role and future directions for surgery in mRCC management. The survival benefits of cytoreductive nephrectomy (CN) shown in the interferon era have encountered increasing disputes in the tyrosine-kinase inhibitor (TKI) and ICI eras. Undoubtedly, several systematic reviews based on retrospective data have supported the survival benefits of CN. Nevertheless, 2 prospective trials, CARMENA and SURTIME, proved that sunitinib as the upfront therapy resulted in noninferior survival outcomes compared with immediate CN. The safety of CN does have solid ground in the current literature. Several studies suggested that preoperative systemic therapy did not seem to aggravate perioperative complications or mortality rates, in experienced centres. Meticulous patient selection is the rule of thumb in the modern management of mRCC patients. The limitations of the existing prognostication models, however, must be acknowledged. Clinicians should adopt a multidisciplinary and holistic approach and contemplate all patient, disease, surgeon and socio-economical factors, before deciding who should go for surgery. The advent of metastasis-directed therapy (MDT) and survival benefits of adjuvant pembrolizumab shown in the oligometastatic subgroup, where complete metastasectomy could be achieved (M1 NED), calls for more comparative studies against upfront ICI combinations. In summary, CN brings survival benefits to well-selected good-to-intermediate-risk mRCC patients. Individualized and multidisciplinary care is pivotal. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Lack of classical astroblastoma features in pediatric MN1::BEND2‐fused brain tumors.
- Author
-
Chapman, Nicholas, Iqbal, Mohammed, Walker, Adam D., Hawes, Debra, Davidson, Tom Belle, Robison, Nathan, Tamrazi, Benita, Ji, Jianling, Krieger, Mark D., and Cotter, Jennifer A.
- Subjects
- *
RADIOSURGERY , *MITOGEN-activated protein kinases , *DNA copy number variations , *RNA analysis , *IRINOTECAN ,CENTRAL nervous system tumors - Abstract
This research letter discusses a case series of pediatric brain tumors with a specific genetic fusion called MN1::BEND2. The study found that these tumors did not exhibit the typical features of astroblastoma, a type of brain tumor. However, the tumors did show DNA methylation profiles consistent with astroblastoma. The study emphasizes the need for further investigation and optimal treatment for these types of tumors. It also highlights the importance of accurate diagnosis and the need for more research on the clinical responses and long-term outcomes of pediatric patients with MN1-altered tumors. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
12. Evaluation of micro-remnant niduses of arteriovenous malformations post-gamma knife radiosurgery by 3D-rotational angiography.
- Author
-
Noda, Ryuichi, Akabane, Atsuya, Kawashima, Mariko, Segawa, Masafumi, Tsunoda, Sho, Wada, Hiroyuki, Watanabe, Makoto, Yamada, Haruyasu, and Inoue, Tomohiro
- Subjects
- *
MAGNETIC resonance angiography , *DIGITAL subtraction angiography , *RADIOSURGERY , *ARTERIOVENOUS malformation , *HOSPITAL patients , *CEREBRAL arteriovenous malformations - Abstract
Purpose: Recent innovations in radiological imaging have enabled the detection of micro-remnant niduses of arteriovenous malformations (AVMs) after gamma knife radiosurgery (GKS), which have not been previously perceptible. Herein, we focus on the difficulty of evaluating micro-remnant AVMs after GKS that are hardly perceptible on conventional examinations and propose integrating follow-up three-dimensional rotational angiography (3D-RA) in the previous gamma plan as a solution. Methods: We retrospectively searched NTT Medical Center Tokyo hospital database for patients with AVMs who underwent both two-dimensional digital subtraction angiography (2D-DSA) and 3D-RA as follow-up for GKS from February 2021 to January 2024. Patients with suspected nidus occlusion on the latest non-contrast-enhanced magnetic resonance angiography (NC-MRA) were included, and contrast-enhanced magnetic resonance angiography (CE-MRA), 2D-DSA, and 3D-RA were evaluated. Results: Twelve patients with 13 AVM sites were defined as having complete nidus occlusion on upfront NC-MRA. On 2D-DSA, seven AVM sites showed the presence of slight remaining AVMs based on the detection of remnant drainage veins, however the nidus was not detected in three cases. Nevertheless, 3D-RA detected micro-remnant niduses in all seven AVM sites, and four patients underwent re-GKS. Nine patients with ten AVM sites also underwent CE-MRA, and six AVM sites were diagnosed with radiation-induced parenchymal injury. Conclusion: Importing the 3D-RA image into the treatment planning has the potential to be more helpful than NC-MRA or CE-MRA to detect micro-remnant AVMs and evaluate the true remnant volume, and may contribute to a more detailed treatment planning, thereby improving the results of GKS retreatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Serum Vascular Endothelial Growth Factor and Endostatin as an Adjunct to Clinical Decision Making in Managing Radiation-induced Changes Post Gamma Knife Radiosurgery in Spetzler Martin Grade 3 Arteriovenous Malformations Patients: A Pilot Study.
- Author
-
Kedia, Shweta, Goyal, Sarvesh, Garg, Kanwaljeet, Phalak, Manoj, Selvi, Arul, Kumar, Anand, Agarwal, Deepak, Singh, Manmohan, Kumar, Rajinder, and Kale, Shashank Sharad
- Subjects
- *
VASCULAR endothelial growth factors , *RADIOSURGERY , *ENDOSTATIN , *MEDIAN (Mathematics) , *ARTERIOVENOUS malformation , *CEREBRAL arteriovenous malformations - Abstract
Radiation induced changes (RIC) are the most common complications observed post Gamma Knife radiosurgery (GKRS) and may be observed within 6–18 months post procedure. It has been observed that almost one-third of RICs are symptomatic and half of them are persistent. There is no way to predict which patients will develop these changes and to what extent. This was a prospective analytical pilot study with the aim of understanding the role of serum vascular endothelial growth factor (VEGF) and endostatin as predictive factors for clinically symptomatic RIC in intracranial arteriovenous malformations (AVMs) of Spetzler Martin (SM) grade 3 being managed with primary GKRS. A total of 15 patients were analyzed; 60% of them had a history of bleed. The median volume of AVM nidus was 4.36 mL. One-third of the patients had no imaging changes suggestive of RIC at 1 year follow-up and 2 of the patients had symptomatic RIC needing intervention. Before GKRS, the median values of serum concentration of endostatin and VEGF were 34.98 ng/mL and 168.37 pg/mL, respectively. The serum values of VEGF at 1 month post GKRS was much lower than the pre-GKRS values but not found to be predictive of RIC. No correlation could be observed with the levels of serum endostatin and RIC. Some patients may develop resistant edema and necrosis post GKRS for intracranial AVMs, which may warrant medical and surgical intervention. Serum biomarkers like VEGF and endostatin may vary in the post GKRS period and can be used to identify at-risk cases, however more studies are needed to decide on appropriate time of sampling and identify clinically relevant predictive factors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Stereotactic Magnetic Resonance-Guided Daily Adaptive SABR (SMART) for Localised Non-Metastatic Pancreatic Cancer: First Reported Clinical Outcomes From the UK.
- Author
-
Nugent, K., Mukherjee, S., Teoh, S., George, B., Martin, A., Gaya, A., Aznar-Garcia, L., Chu, K., Robinson, M., Maughan, T., and Good, J.
- Subjects
- *
RADIATION protection , *DOSE-response relationship (Radiation) , *RADIOTHERAPY , *ABDOMINAL pain , *RADIOSURGERY , *RADIATION dosimetry , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *MAGNETIC resonance imaging , *PANCREATIC tumors , *CANCER chemotherapy , *MEDICAL records , *ACQUISITION of data , *PROGRESSION-free survival , *SURVIVAL analysis (Biometry) , *CONFIDENCE intervals , *CANCER fatigue , *OVERALL survival , *NAUSEA , *HEMORRHAGE - Abstract
Prognosis of locally advanced pancreatic cancer (LAPC) remains poor with limited therapeutic options. Radiation therapy in pancreatic cancer has been restricted by the disease's proximity to radiosensitive organs at risk (OAR). However, stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) has demonstrated promise in delivering ablative doses safely. We sought to report clinical outcomes from a UK-based Compassionate Access Programme that provided access to SMART to patients with LAPC. This was a registry retrospective study conducted at a single centre with access to SMART. Patients with LAPC were treated with prescription dose of 40 Gy in 5 fractions. The planning objective was that 98% of PTV received ≥95% of the prescribed dose, prioritising duodenal, stomach and bowel UK SABR consortium constraints. Daily online adaptation was performed using magnetic resonance guidance and on-table re-optimisation. 0–3 months and > 3-month post-treatment-related toxicities, local progression-free survival, metastatic-free survival and overall survival were evaluated. 55 patients were treated with SMART at our institution from 2020 to 2022. Median follow-up from date of diagnosis was 17 months (range 5–37 months). Median age was 69.87% of patients underwent induction chemotherapy. 71% of patients reported 0–1 grade acute toxicity only. No grade >3 acute toxicity was reported. 5 patients (9%) reported a grade 3 toxicity (fatigue, nausea, abdominal pain, duodenal stricture). No grade >3 toxicity after 3 months was reported. 6 (10%) of patients had grade 3 toxicity (fatigue, nausea, abdominal pain, duodenal haemorrhage). Median local PFS post diagnosis was 17 months (95% CI 15.3–18.7). Median OS post diagnosis was 19 months (95% CI 15.9–22.1). One-year local control post SMART was 65%. This is the first UK-reported experience of MR-guided daily adaptive pancreatic SABR. SMART shows promise in delivering ablative doses with acceptable toxicity rates and good clinical outcomes. • No acute or late grade >3 toxicity reported. • Majority of patients (71%) experienced no or grade 1 only acute toxicity. • Acute and late G3 toxicity incidence was 9% and 10% respectively. • 65% of all patients maintained local control at 1 year post SMART. • Median OS was 21 months with chemotherapy followed by consolidatory pancreas SMART. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. The Role of Radiation Therapy in the Management of Prostate Cancer and Posttreatment Imaging Appearances.
- Author
-
Ghosh, Soumyadeep, Rosen, Daniel B., Pandey, Ankur, Nakrour, Nabih, Prajapati, Priyanka, Harisinghani, Mukesh, and Kamran, Sophia C.
- Subjects
PROTON therapy ,RADIOTHERAPY ,CANCER relapse ,COMPUTED tomography ,PROSTATE tumors ,MAGNETIC resonance imaging ,RADIOSURGERY ,POSITRON emission tomography ,CELL lines ,PROSTATE ,COMPUTERS in medicine ,RADIATION doses - Abstract
Prostate cancer remains a significant global health concern, necessitating continuous research and innovation in treatment modalities. This review explores the currently employed techniques in radiation dose planning and tumor irradiation in the context of prostate cancer management. In addition, we delve into the nuances of expected posttreatment magnetic resonance imaging (MRI) appearances within the gland or in the prostate bed, postradiation tumor recurrence, and its mimics. Radiation therapy (RT) has evolved as a cornerstone in prostate cancer treatment, offering both curative and palliative solutions. Recent developments have seen the emergence of advanced techniques such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT), allowing for precise targeting of cancer cells while minimizing damage to surrounding healthy tissue. The avoidance of normal tissue dose through more conformal dose distribution as in IMRT or proton therapy, improved imaging modalities as in multiparametric magnetic resonance imaging (mpMRI) and prostate positron emission tomography (PET), interventional separation of critical structures from the prostate target, and many other techniques can greatly reduce the side effects of RT. These advancements enhance treatment efficacy and reduce the risk of side effects, promoting improved patient outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Stereotactic radiosurgery and radiotherapy for brainstem metastases: An international multicenter analysis.
- Author
-
Ehret, Felix, Rueß, Daniel, Blanck, Oliver, Fichte, Susanne, Chatzikonstantinou, Georgios, Wolff, Robert, Mose, Lucas, Mose, Stephan, Fortmann, Thomas, Lehrke, Ralph, Turna, Menekse, Caglar, Hale Basak, Mortasawi, Farshin, Bleif, Martin, Krug, David, Ruge, Maximilian I., Fürweger, Christoph, and Muacevic, Alexander
- Subjects
STEREOTACTIC radiotherapy ,STEREOTACTIC radiosurgery ,BRAIN stem ,KARNOFSKY Performance Status ,OVERALL survival - Abstract
Brainstem metastases (BSM) present a significant neuro‐oncological challenge, resulting in profound neurological deficits and poor survival outcomes. Stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) offer promising therapeutic avenues for BSM despite their precarious location. This international multicenter study investigates the efficacy and safety of SRS and FSRT in 136 patients with 144 BSM treated at nine institutions from 2005 to 2022. The median radiographic and clinical follow‐up periods were 6.8 and 9.4 months, respectively. Predominantly, patients with BSM were managed with SRS (69.4%). The median prescription dose and isodose line for SRS were 18 Gy and 65%, respectively, while for FSRT, the median prescription dose was 21 Gy with a median isodose line of 70%. The 12‐, 24‐, and 36‐month local control (LC) rates were 82.9%, 71.4%, and 61.2%, respectively. Corresponding overall survival rates at these time points were 61.1%, 34.7%, and 19.3%. In the multivariable Cox regression analysis for LC, only the minimum biologically effective dose was significantly associated with LC, favoring higher doses for improved control (in Gy, hazard ratio [HR]: 0.86, p <.01). Regarding overall survival, good performance status (Karnofsky performance status, ≥90%; HR: 0.43, p <.01) and prior whole brain radiotherapy (HR: 2.52, p <.01) emerged as associated factors. In 14 BSM (9.7%), treatment‐related adverse events were noted, with a total of five (3.4%) radiation necrosis. SRS and FSRT for BSM exhibit efficacy and safety, making them suitable treatment options for affected patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Single versus multiple fraction stereotactic radiosurgery for medium-sized brain metastases (4-14 cc in volume): reducing or fractionating the radiosurgery dose?
- Author
-
Reinhardt, Philipp, Ahmadli, Uzeyir, Uysal, Emre, Shrestha, Binaya Kumar, Schucht, Philippe, Hakim, Arsany, and Ermis¸, Ekin
- Subjects
STEREOTACTIC radiosurgery ,BRAIN tumors ,RADIOSURGERY ,MAGNETIC resonance imaging ,RETROSPECTIVE studies - Abstract
Background and purpose: Stereotactic radiosurgery (SRS) of brain metastases (BM) and resection cavities is a widely used and effective treatment modality. Based on target lesion size and anatomical location, single fraction SRS (SF-SRS) or multiple fraction SRS (MF-SRS) are applied. Current clinical recommendations conditionally recommend either reduced dose SF-SRS or MF-SRS for medium-sized BM (2--2.9 cm in diameter). Despite excellent local control rates, SRS carries the risk of radionecrosis (RN). The purpose of this study was to assess the 12- months local control (LC) rate and 12-months RN rate of this specific patient population. Materials and methods: This single-center retrospective study included 54 patients with medium-sized intact BM (n=28) or resection cavities (n=30) treated with either SF-SRS or MF-SRS. Follow-up MRI was used to determine LC and RN using a modification of the "Brain Tumor Reporting and Data System" (BT-RADS) scoring system. Results: The 12-month LC rate following treatment of intact BM was 66.7% for SF-SRS and 60.0% for MF-SRS (p=1.000). For resection cavities, the 12-month LC rate was 92.9%% after SF-SRS and 46.2% after MF-SRS (p=0.013). For intact BM, RN rate was 17.6% for SF-SRS and 20.0% for MF-SRS (p=1.000). For resection cavities, RN rate was 28.6% for SF-SRS and 20.0% for MF-SRS (p=1.000). Conclusion: Patients with intact BM showed no statistically significant differences in 12-months LC and RN rate following SF-SRS or MF-SRS. In patients with resection cavities the 12-months LC rate was significantly better following SF-SRS, with no increase in the RNFS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Evaluation of the Effect of Radiosurgery for Target and Non-Target Lesions in Patients with Brain Metastases Using RANO-BM Criteria.
- Author
-
Popov, Veselin, Raycheva, Gabriela, Graklanov, Vasko, Uchikov, Petar, and Grudeva-Popova, Zhanet
- Subjects
RADIOSURGERY ,BRAIN damage ,STEREOTACTIC radiosurgery ,NON-small-cell lung carcinoma ,SECONDARY primary cancer ,STEREOTAXIC techniques ,LUNGS - Abstract
Objectives: The current therapeutic indications of radiosurgery are constantly expanding. Magnetic resonance imaging (MRI) has an important role in the diagnostic and post-therapeutic period of primary and secondary brain tumor formations. Methods: A total of 66 patients with verified cancer disease and brain metastases were separated into two groups. The first group includes 34 patients with primary non-small cell lung cancer and the second one 32 patients with other types of primary cancer. All of them received high-dose radiotherapy in 1–5 fractions. The number, size, and location of the treated lesions responded to robotic stereotactic radiosurgery criteria. The Response Assessment Criteria for Brain Metastases (RANO-BM) is an international multidisciplinary group of experts who developed acceptable criteria for assessing brain metastases. Before treatment and on the first, third, sixth month after radiosurgery, a MRI and blood tests were performed. Results: Treated lesions were separated into four groups depending on the results – complete response, partial response, progressive disease, and stable disease. In both groups of patients, the percentage of complete or partial response had increased in the third and sixth months. Conclusion: The results give us a reason not to recommend an MRI 1 month after treatment if the patient doesn't have any new neurological symptoms, because there may be a pseudo-progression. MRI results valued by RANO-BM criteria give us a good option to evaluate brain metastases on the third and sixth month after after stereotactic radiosurgery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Stereotactic ablative radiotherapy versus conventional fractionated radiotherapy for clinical early‐stage non‐small‐cell lung cancer: a population‐based study.
- Author
-
Chen, Hung‐Jen, Cheng, Wen‐Chien, Tu, Chih‐Yen, Hsia, Te‐Chun, Lin, Yu‐Sen, Fang, Hsin‐Yuan, Li, Chia‐Chin, and Chien, Chun‐Ru
- Subjects
- *
RADIOTHERAPY , *RESEARCH funding , *QUESTIONNAIRES , *POPULATION health , *RADIOSURGERY , *RETROSPECTIVE studies , *REPORTING of diseases , *DESCRIPTIVE statistics , *STEREOTAXIC techniques , *MEDICAL records , *ACQUISITION of data , *LUNG cancer , *RADIATION doses , *COMPARATIVE studies , *SURVIVAL analysis (Biometry) , *CONFIDENCE intervals , *PROPORTIONAL hazards models - Abstract
Introduction: The use of stereotactic ablative radiotherapy (SABR) over conventional fractionated radiotherapy (CFRT) for early‐stage non‐small‐cell lung cancer (NSCLC) has been advocated, but is also debated in the literature. Methods: In this retrospective cohort study, we adopted a target trial emulation framework to identify eligible patients diagnosed between 2011 and 2021 using the Taiwan Cancer Registry. In the primary analysis, the overall survival (OS) was the primary endpoint, whereas incidences of lung cancer mortality and radiation pulmonary toxicity were the secondary endpoints. Extensive supplementary analyses were also conducted. Results: We included 351 patients in the primary analysis and found that the OS was not significantly different between the SABR (n = 290) and CFRT (n = 61) groups. The propensity score weighting adjusted hazard ratio of death was 0.75 (95% confidence interval 0.53–1.07, p = 0.118). The secondary endpoints and supplementary analyses showed no significant differences. Conclusions: The OS of patients with early‐stage NSCLC treated with SABR was not significantly different from that of patients treated with CFRT alone. The results of the relevant ongoing clinical trials are eagerly awaited. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Stereotactic radio-neurosurgery for jugular foramen schwannomas.
- Author
-
Bourhila, Camil, Cotrutz, Cristian, Daniel, Roy Thomas, George, Mercy, Schiappacasse, Luis, Patin, David, Levivier, Marc, and Tuleasca, Constantin
- Subjects
- *
MEDULLA oblongata , *CRANIAL nerves , *STEREOTACTIC radiosurgery , *UNIVERSITY hospitals , *PARALYSIS , *RADIOSURGERY - Abstract
Background: Stereotactic radiosurgery (SRS) represents a minimally invasive and valuable alternative for jugular foramen schwannomas (JFS), both as upfront and/or adjuvant treatment (in hybrid approaches). Methods: We conducted a retrospective review of our cases treated at the Lausanne University Hospital (CHUV) from June 2010 to October 2023. Eleven patients underwent SRS, among whom three had prior surgery, two in our center in the frame of a planned combined approach and one in another center. Two patients received "volume-staged" SRS. The mean age at SRS was 60 years (median 68; range 29–83). Cranial nerve (CN) symptoms were present in six patients, while five were asymptomatic. The mean tumor volume at SRS was 2.1 cc (median 1.2; range 0.068–7.3 cc), with a 12 Gy marginal dose prescribed in all cases. Results: The mean follow-up period was 3.9 years (median 2, range 1–7). Cranial nerve function improved after SRS in six patients, while five remained stable. At the last follow-up, all tumors showed a decrease in volume, except for one patient, who underwent surgery at 18 months after SRS, for volumetric increase at 6 and 12 months, with further XII−th CN palsy and medulla oblongata compression. Although tumor decreased at 18 months, such patient needed microsurgical resection for symptom persistence and was further controlled. The mean tumor volume at 1 year post-SRS was 1.6 cc (median 0.55; range 0.028–7.77 cc), at 2 years was 1.31 cc (median 0.76; range 0.19–5), and at 3 years was 1.32 cc (median 0.59; range 0.23–4.8). No adverse radiation events were observed. Conclusions: Stereotactic radiosurgery is considered a safe and effective treatment for jugular foramen schwannomas, ensuring high rates of tumor control in all patients over the long term. The cranial nerve function improved after SRS in the 6 patients who had deficits and the other 5 patients who had no deficits remained asymptomatic. For larger tumors, combined/hybrid approaches can be a valuable alternative, to obtain tumor control and to preserve neurological function. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. A Multidisciplinary Update on Treatment Modalities for Metastatic Spinal Tumors with a Surgical Emphasis: A Literature Review and Evaluation of the Role of Artificial Intelligence.
- Author
-
Houston, Rebecca, Desai, Shivum, Takayanagi, Ariel, Quynh Thu Tran, Christina, Mortezaei, Ali, Oladaskari, Alireza, Sourani, Arman, Siddiqi, Imran, Khodayari, Behnood, Ho, Allen, and Hariri, Omid
- Subjects
- *
PREDICTION models , *NEUROSURGERY , *INTERPROFESSIONAL relations , *ARTIFICIAL intelligence , *SPINAL tumors , *MINIMALLY invasive procedures , *RADIOSURGERY , *RADIO frequency therapy , *METASTASIS , *STEREOTAXIC techniques , *CATHETER ablation , *SEQUENCE analysis , *ALGORITHMS , *HEALTH care teams - Abstract
Simple Summary: As the treatment modalities for spinal metastatic tumors continue to evolve, the goal of improving the quality of life of patients with spinal metastases becomes more easily attainable. The best patient care is a combination of multiple treatment modalities, surgical and nonsurgical, that maximizes the advantages of each modality and should be individualized according to their unique clinical presentation, pathology, and life expectancy. In this review article, we highlight various new treatment options that have shown promising improvements in patient outcomes. Notably, we discuss the potential clinical applications of AI and NGS in the treatment of spinal metastases. Spinal metastases occur in up to 40% of patients with cancer. Of these cases, 10% become symptomatic. The reported incidence of spinal metastases has increased in recent years due to innovations in imaging modalities and oncological treatments. As the incidence of spinal metastases rises, so does the demand for improved treatments and treatment algorithms, which now emphasize greater multidisciplinary collaboration and are increasingly customized per patient. Uniquely, we discuss the potential clinical applications of AI and NGS in the treatment of spinal metastases. Material and Methods: A PubMed search for articles published from 2000 to 2023 regarding spinal metastases and artificial intelligence in healthcare was completed. After screening for relevance, the key findings from each study were summarized in this update. Results: This review summarizes the evidence from studies reporting on treatment modalities for spinal metastases, including minimally invasive surgery (MIS), external beam radiation therapy (EBRT), stereotactic radiosurgery (SRS), CFR-PEEK instrumentation, radiofrequency ablation (RFA), next-generation sequencing (NGS), artificial intelligence, and predictive models. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Stereotactic Radiosurgery in Metastatic Spine Disease—A Systemic Review of the Literature.
- Author
-
Palacio Giraldo, Adriana, Sohm, David, Neugebauer, Johannes, Leone, Gianpaolo, Bergovec, Marko, and Dammerer, Dietmar
- Subjects
- *
DISEASE management , *RADIOSURGERY , *SPINAL tumors , *TREATMENT effectiveness , *META-analysis , *METASTASIS , *SYSTEMATIC reviews , *MEDLINE , *QUALITY of life , *PAIN management , *SURVIVAL analysis (Biometry) , *ONLINE information services , *RADIATION doses - Abstract
Simple Summary: Patients with metastatic spine disease face significant challenges and limitations with current therapy options. The aim of this study is to explore the existing literature on spinal stereotactic radiosurgery (SRS) to understand its potential and effectiveness in managing this condition. The motivation stems from a desire to contribute to the field of medical science and improve patient care. This study highlights SRS as a safe and effective technique for managing spinal metastases. It offers good pain control and tumor control with minimal complications. This review strengthens the understanding of SRS for managing spinal metastases, emphasizing its efficacy and the need for personalized treatment plans. Overall, the findings highlight the evolving role of SRS in a multidimensional approach to managing spinal metastases. Background: This study investigated the efficacy of stereotactic radiosurgery (SRS) in managing spinal metastasis. Traditionally, surgery was the primary approach, but SRS has emerged as a promising alternative. Objective: The study aims to evaluate the efficacy of stereotactic radiosurgery in the management of spinal metastasis in terms of local tumor control, patient survival, and quality of life, identifying both advantages and limitations of SRS. Methods: Through an extensive literature search in PubMed with cross-referencing, relevant full-text-available papers published between 2012 and 2022 in English or German were included. The search string used was "metastatic spine diseases AND SRS OR stereotactic radiosurgery". Results: There is growing evidence of SRS as a precise and effective treatment. SRS delivers high radiation doses while minimizing exposure to critical neural structures, offering benefits like pain relief, limited tumor growth, and a low complication rate, even for tumors resistant to traditional radiation therapies. SRS can be a primary treatment for certain metastatic cases, particularly those without spinal cord compression. Conclusions: SRS appears to be a preferable option for oligometastasis and radioresistant lesions, assuming there are no contraindications. Further research is necessary to refine treatment protocols, determine optimal radiation dose and fractionation schemes, and assess the long-term effects of SRS on neural structures. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Hypopituitarism after gamma knife radiosurgery for pituitary adenomas: long-term results from a single-center experience.
- Author
-
Yu, Jinxiu, Fu, Jiaming, Li, Yanli, Hu, Guangxin, Hu, Guanye, Hu, Wentao, Liu, Detian, and Fu, Junyi
- Subjects
- *
PITUITARY dwarfism , *RADIOSURGERY , *PITUITARY tumors , *HYPOPITUITARISM , *CANCER invasiveness - Abstract
Objective: The aim of this study was to investigate the incidence and risk factors of new-onset hypopituitarism after gamma knife radiosurgery (GKRS) for pituitary adenomas in a single center. Methods: In this retrospective study, 241 pituitary adenoma patients who underwent GKRS from 1993 to 2016 were enrolled. These patients had complete endocrine, imaging, and clinical data before and after GKRS. The median follow-up time was 56.0 (range, 12.7–297.6) months. Results: Fifty patients (20.7%) developed new-onset hypopituitarism after GKRS, including hypogonadism (n = 22), hypothyroidism (n = 29), hypocortisolism (n = 20), and growth hormone deficiency (n = 4). The median time to new-onset hypopituitarism was 44.1 (range, 13.5–141.4) months. The rates of new-onset hypopituitarism were 7%, 16%, 20%, 39%, and 45% at 1, 3, 5, 10, and 15 years, respectively. For those patients treated with a single GKRS, sex (p = 0.012), suprasellar extension (p = 0.048), tumor volume (≥ 5 cm3) (p < 0.001), tumor progression (p = 0.001), pre-existing hypopituitarism (p = 0.011), and previous surgery (p = 0.009) were significantly associated with new-onset hypopituitarism in univariate analysis. In the multivariate analysis, tumor volume (≥ 5 cm3) and tumor progression were associated with new-onset hypopituitarism (hazard ratio [HR] = 3.401, 95% confidence interval [CI] = 1.708–6.773, p < 0.001 and HR = 3.594, 95% CI = 1.032–12.516, p = 0.045, respectively). For patients who received 2 or more times GKRS, no risk factors associated with new-onset hypopituitarism were found. Conclusion: New-onset hypopituitarism was not uncommon after GKRS for pituitary adenomas. In this study, large tumor volume (≥ 5 cm3) and tumor progression were associated with new-onset hypopituitarism after a single GKRS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Surgical and radiosurgical outcomes for Koos grade 3 vestibular schwannomas.
- Author
-
Kamogawa, Misaki, Tanino, Shin, Miyahara, Kosuke, Shuto, Takashi, Matsunaga, Shigeo, Okada, Tomu, Noda, Naoyuki, Sekiguchi, Noriaki, Suzuki, Koji, Tanaka, Yusuke, and Uriu, Yasuhiro
- Abstract
This study aimed to reveal the preferred initial treatment for Koos grade 3 vestibular schwannomas (VS). We performed a two-institutional retrospective study on 21 patients with Koos grade 3 VS undergoing resection at Yokohama Medical Center and 37 patients undergoing radiosurgery at Yokohama Rosai Hospital from 2010 to 2021. Tumor control, complications, and functional preservation were compared. The median pre-treatment volume and follow-up duration were 2845 mm3 and 57.0 months, respectively, in the resection group and 2127 mm3 and 81.7 months, respectively, in the radiosurgery group. In the resection group, 16 (76.2%) underwent gross total resection, and three patients (14.3%) experienced regrowth; however, no one required additional treatment. In the radiosurgery group, the tumor control rate was 86.5%, and three cases (8.1%) required surgical resection because of symptomatic brainstem compression. Kaplan–Meier analyses revealed that tumors with delayed continuous enlargement and large thin-walled cysts were significantly associated with poor prognostic factors (p = 0.0027, p < 0.001). The pre-radiosurgery growth rate was also associated with the volume increase (p = 0.013). Two cases (9.5%) required additional operation due to complications such as post-operative hematoma and cerebrospinal fluid leaks in the resection group, whereas temporary cranial neuropathies were observed in the radiosurgery group. Two patients (9.5%) had poor facial nerve function (House–Brackmann grading grade 3) in the resection group, while no one developed facial paresis in the radiosurgery group. Trigeminal neuropathy improved only in the resection group.Radiosurgery can be considered for the treatment of Koos grade 3 VS for functional preservation. However, resection may also be considered for patients with severe trigeminal neuropathy or a high risk of volume increments, such as large thin-walled cysts and rapid pre-treatment growth. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Embolization Prior to Radiosurgery in Treatment of Arteriovenous Malformations: Defining Radiosurgery Target Dose with Nidal Volume Reduction.
- Author
-
Young, Michael, Muram, Sandeep, Enriquez-Marulanda, Alejandro, Pettersson, Samuel D., Taussky, Philipp, Aghdam, Nima, and Ogilvy, Christopher S.
- Subjects
- *
STEREOTACTIC radiosurgery , *ARTERIOVENOUS malformation , *RADIOSURGERY , *MAGNETIC resonance imaging , *THERAPEUTICS - Abstract
Arteriovenous malformations (AVMs) can be treated with observation, surgery, embolization, stereotactic radiosurgery (SRS), or a combination of therapies. SRS has been used for AVMs that pose a high risk of surgery, such as in deep or eloquent anatomic locations. Smaller AVMs, <3 cm, have been shown to have higher rates of complete obliteration after SRS. For AVMs that are a larger size, embolization prior to SRS has been used to reduce the size of the AVM nidus. In this study we analyzed embolization prior to SRS to reduce nidal volume and describe imaging techniques to target for SRS post embolization. We retrospectively reviewed all patients at a single academic institution treated with embolization prior to SRS for treatment of AVMs. We then used contrast enhanced magnetic resonance imaging (MRI) to contour AVM volumes based on pre-embolization imaging and compared to post-embolization imaging. Planned AVM volume prior to embolization was then compared to actual treated AVM volume. We identified 11 patients treated with embolization prior to SRS from 2011–2023. Median AVM nidal volume prior to embolization was 7.69 mL and post embolization was 3.61 ML (P < 0.01). There was a 45.5% obliteration rate at follow up in our series, with 2 minor complications related to radiosurgery. In our cohort, embolization prior to SRS resulted in a statistically significant reduction in AVM nidal volume. Therefore, embolization prior to SRS can result in dose reduction at time of SRS treatment allowing for decreased risk of SRS complications without higher embolization complication rates. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Automatic Segmentation of Vestibular Schwannomas: A Systematic Review.
- Author
-
Nernekli, Kerem, Persad, Amit R., Hori, Yusuke S., Yener, Ulas, Celtikci, Emrah, Sahin, Mustafa Caglar, Sozer, Alperen, Sozer, Batuhan, Park, David J., and Chang, Steven D.
- Subjects
- *
CONVOLUTIONAL neural networks , *SCHWANNOMAS , *BENIGN tumors , *TUMOR growth , *TRANSFORMER models - Abstract
Vestibular schwannomas (VSs) are benign tumors often monitored over time, with measurement techniques for assessing growth rates subject to significant interobserver variability. Automatic segmentation of these tumors could provide a more reliable and efficient for tracking their progression, especially given the irregular shape and growth patterns of VS. Various studies and segmentation techniques employing different Convolutional Neural Network architectures and models, such as U-Net and convolutional-attention transformer segmentation, were analyzed. Models were evaluated based on their performance across diverse datasets, and challenges, including domain shift and data sharing, were scrutinized. Automatic segmentation methods offer a promising alternative to conventional measurement techniques, offering potential benefits in precision and efficiency. However, these methods are not without challenges, notably the "domain shift" that occurs when models trained on specific datasets underperform when applied to different datasets. Techniques such as domain adaptation, domain generalization, and data diversity were discussed as potential solutions. Accurate measurement of VS growth is a complex process, with volumetric analysis currently appearing more reliable than linear measurements. Automatic segmentation, despite its challenges, offers a promising avenue for future investigation. Robust well-generalized models could potentially improve the efficiency of tracking tumor growth, thereby augmenting clinical decision-making. Further work needs to be done to develop more robust models, address the domain shift, and enable secure data sharing for wider applicability. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Gamma-knife radiosurgery in acromegaly: the results from the Croatian acromegaly registry.
- Author
-
Škorić Polovina, Tanja, Režić, Tanja, Kraljević, Ivana, Heinrich, Zdravko, Solak, Mirsala, Dušek, Tina, Balaško, Annemarie, Zibar Tomšić, Karin, and Kaštelan, Darko
- Subjects
- *
ACROMEGALY , *HYPOPITUITARISM , *RADIOSURGERY , *HORMONE deficiencies , *PITUITARY tumors , *THERAPEUTICS , *CROATS - Abstract
The aim of our study was to evaluate the efficacy and safety of Leksell gamma-knife radiosurgery in the treatment of residual growth hormone-secreting pituitary adenomas after the surgery. We conducted a retrospective analysis of 23 acromegaly patients treated with gamma-knife radiosurgery between 1996 and 2019. The therapeutic success of radiosurgery was defined as IGF-1 normalization without suppressive medication (complete response) or as IGF-1 normalization with medication (partial response). The median follow-up was 57 (10–198) months. Complete response was achieved in 11 patients (47.8%) with actuarial remission rates of 17.4%, 26.1%, 39.1% and 47.8% at 1, 2, 4, and 7 years, respectively. The median time to complete the response was 21 (6–85) months. Partial response was achieved in another nine patients (39.1%) after a median time of 48 (6–144) months from radiosurgery. Patients who achieved complete remission had significantly lower IGF-1 levels before radiosurgery (p = 0.016) as well as smaller tumour volume (p = 0.016) and radiologically less invasive tumours (p = 0.022) in comparison to patients who did not achieve IGF-1 normalization. Tumour growth control after radiosurgery was established in all patients. During the follow-up, new hormone deficiencies were found in seven patients (30.4%) which corresponds to the incidence of one new case of hypopituitarism per 7.1 patient years. Gamma-knife radiosurgery offers endocrine remission and tumour growth control in a substantial proportion of patients with GH-secreting adenomas. Given the high cost of life-long medical treatment and a moderate risk of radiation-induced side effects, radiosurgery for growth hormone-secreting pituitary adenomas should be considered in all patients with residual tumours. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Controversies in neuro-oncology: Focal proton versus photon radiation therapy for adult brain tumors.
- Author
-
Eekers, Danielle B P, Zegers, Catharina M L, Ahmed, Kamran A, Amelio, Dante, Gupta, Tejpal, Harrabi, Semi Ben, Kazda, Tomas, Scartoni, Daniele, Seidel, Clemens, Shih, Helen A, and Minniti, Giuseppe
- Subjects
- *
BRAIN tumors , *PHOTON emission , *RADIOTHERAPY , *ADULTS , *BENIGN tumors - Abstract
Radiation therapy (RT) plays a fundamental role in the treatment of malignant and benign brain tumors. Current state-of-the-art photon- and proton-based RT combines more conformal dose distribution of target volumes and accurate dose delivery while limiting the adverse radiation effects. PubMed was systematically searched from from 2000 to October 2023 to identify studies reporting outcomes related to treatment of central nervous system (CNS)/skull base tumors with PT in adults. Several studies have demonstrated that proton therapy (PT) provides a reduced dose to healthy brain parenchyma compared with photon-based (xRT) radiation techniques. However, whether dosimetric advantages translate into superior clinical outcomes for different adult brain tumors remains an open question. This review aims at critically reviewing the recent studies on PT in adult patients with brain tumors, including glioma, meningiomas, and chordomas, to explore its potential benefits compared with xRT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Harnessing the Power of Radiotherapy for Lung Cancer: A Narrative Review of the Evolving Role of Magnetic Resonance Imaging Guidance.
- Author
-
Cheng, Sarah Hsin, Lee, Shao-Yun, and Lee, Hsin-Hua
- Subjects
- *
RADIOTHERAPY , *ARTIFICIAL intelligence , *PARTICLE accelerators , *DISEASE management , *COMPUTED tomography , *ANTINEOPLASTIC agents , *MAGNETIC resonance imaging , *TREATMENT effectiveness , *RADIOSURGERY , *LUNG tumors , *CHEST (Anatomy) , *BRACHIAL plexus - Abstract
Simple Summary: MR-Linac is a novel magnetic resonance imaging (MRI)-guided radiotherapy (IGRT) that combines MRI with a linear accelerator (Linac). Although radiation therapy (RT) for lung cancer has traditionally been managed with a computed tomography (CT)-based workflow, an MR-Linac-based workflow would be able to address the many limitations of current practice. This narrative review summarizes the latest developments in MR-Linac lung cancer treatment, as well as its boundaries. Future research directions are also highlighted. Compared with computed tomography (CT), magnetic resonance imaging (MRI) traditionally plays a very limited role in lung cancer management, although there is plenty of room for improvement in the current CT-based workflow, for example, in structures such as the brachial plexus and chest wall invasion, which are difficult to visualize with CT alone. Furthermore, in the treatment of high-risk tumors such as ultracentral lung cancer, treatment-associated toxicity currently still outweighs its benefits. The advent of MR-Linac, an MRI-guided radiotherapy (RT) that combines MRI with a linear accelerator, could potentially address these limitations. Compared with CT-based technologies, MR-Linac could offer superior soft tissue visualization, daily adaptive capability, real-time target tracking, and an early assessment of treatment response. Clinically, it could be especially advantageous in the treatment of central/ultracentral lung cancer, early-stage lung cancer, and locally advanced lung cancer. Increasing demands for stereotactic body radiotherapy (SBRT) for lung cancer have led to MR-Linac adoption in some cancer centers. In this review, a broad overview of the latest research on imaging-guided radiotherapy (IGRT) with MR-Linac for lung cancer management is provided, and development pertaining to artificial intelligence is also highlighted. New avenues of research are also discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. The Landscape of Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Cancer (RCC).
- Author
-
Moreno-Olmedo, Elena, Sabharwal, Ami, Das, Prantik, Dallas, Nicola, Ford, Daniel, Perna, Carla, and Camilleri, Philip
- Subjects
- *
KIDNEY tumors , *KIDNEY abnormalities , *CANCER patient medical care , *RADIOSURGERY , *RADIO frequency therapy , *PATIENT care , *HEMODIALYSIS , *RENAL cell carcinoma , *ALTERNATIVE medicine , *CELL death , *CATHETER ablation , *TUMOR classification , *HEALTH care teams - Abstract
Simple Summary: RCC has traditionally been considered radioresistant, with surgery being the gold standard for primary localized RCC. However, not all patients are suitable for surgery and percutaneous, non-surgical options are invasive, with significant limitations. SABR is a non-invasive advanced RT technique that delivers high doses accurately. Growing evidence supports SABR as a definitive alternative therapy for medically inoperable patients, those who decline surgery, are unfit for invasive ablation, or are at high-risk of requiring postoperative dialysis. SABR has shifted the renal radioresistance paradigm, widening the therapeutic window. Additionally, SABR is increasingly used for locally recurrent, oligoprogressive, and oligometastatic disease. This review aims to support the use of SABR across various stages of RCC disease and explore future directions. The overall landscape of RCC is promising, and we are confident that our update will stimulate further research in this field and contribute to the advancement of patient care. Renal cell cancer (RCC) has traditionally been considered radioresistant. Because of this, conventional radiotherapy (RT) has been predominantly relegated to the palliation of symptomatic metastatic disease. The implementation of stereotactic ablative radiotherapy (SABR) has made it possible to deliver higher ablative doses safely, shifting the renal radioresistance paradigm. SABR has increasingly been adopted into the multidisciplinary framework for the treatment of locally recurrent, oligoprogressive, and oligometastatic disease. Furthermore, there is growing evidence of SABR as a non-invasive definitive therapy in patients with primary RCC who are medically inoperable or who decline surgery, unsuited to invasive ablation (surgery or percutaneous techniques), or at high-risk of requiring post-operative dialysis. Encouraging outcomes have even been reported in cases of solitary kidney or pre-existing chronic disease (poor eGFR), with a high likelihood of preserving renal function. A review of clinical evidence supporting the use of ablative radiotherapy (SABR) in primary, recurrent, and metastatic RCC has been conducted. Given the potential immunogenic effect of the high RT doses, we also explore emerging opportunities to combine SABR with systemic treatments. In addition, we explore future directions and ongoing clinical trials in the evolving landscape of this disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Retrospective Analysis of Efficacy and Toxicity of Stereotactic Body Radiotherapy and Surgical Resection of Adrenal Metastases from Solid Tumors.
- Author
-
Lütscher, Jamie, Gelpke, Hans, Zehnder, Adrian, Mauti, Laetitia, Padevit, Christian, John, Hubert, Batifi, Nidar, Zwahlen, Daniel Rudolf, Förster, Robert, and Schröder, Christina
- Subjects
- *
DRUG toxicity , *PATIENT selection , *RADIOSURGERY , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *METASTASIS , *SURGICAL complications , *ADRENALECTOMY , *ADRENAL tumors , *PROGRESSION-free survival , *OVERALL survival , *COMORBIDITY - Abstract
Simple Summary: The adrenal glands represent a frequent localization area for metastases of various primary tumors. The standard of care for treating adrenal metastases is currently surgical resection, but radiotherapy is becoming a feasible and well-tolerated treatment alternative. However, the literature shows contradictory results regarding the optimal local treatment for adrenal metastases. This study analyzed oncological outcomes (local control, progression free survival, and overall survival) and complication rates after stereotactic body radiotherapy or surgical resection of adrenal metastases to further asses the benefits of stereotactic body radiotherapy. To our knowledge, this analysis is the first direct comparison of stereotactic body radiotherapy and adrenalectomy for adrenal metastases. Background: This single-center retrospective study aimed to evaluate the efficacy and toxicity profiles of stereotactic body radiotherapy (SBRT) and surgical resection in patients with adrenal metastases originating from solid tumors. Methods/Materials: Patients with advanced tumor conditions or comorbidities typically received SBRT, whereas those considered physically fit underwent standard surgical treatment. Endpoints included local control (LC), progression free survival (PFS), overall survival (OS), and complication rates (CR). Results: 41 patients with 48 adrenal metastases were included, with 27 (65.9%) patients receiving SBRT and 14 (34.1%) patients undergoing adrenalectomy. One- and two-year LC values were 100% for both periods after adrenalectomy, and 70.0% and 52.5% after SBRT (p = 0.001). PFS showed values of 40.2% and 32.1% at one and two years after adrenalectomy and of 10.6% for both periods after SBRT (p = 0.223). OS was 83.3% both one and two years after surgery and 67.0% and 40.2% after SBRT (p = 0.031). There was no statistically significant difference between the two groups regarding acute complications (p = 0.123). Conclusion: Despite potential confounders, adrenalectomy exhibited statistically significant superior LC and OS compared to SBRT in managing adrenal metastases, while both treatment methods displayed acceptable toxicity profiles. However, patient selection bias must be taken into account when directly comparing the two therapy modalities. Nevertheless, the study provides new and important results for the scientific and medical communities regarding oncological outcomes after SBRT or surgical resection of adrenal metastases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. The potential of integrating stereotactic ablative radiotherapy techniques with hyperfractionation for lung cancer.
- Author
-
Chiou, Chi‐Chuan, Wu, Yuan‐Hung, Huang, Pin‐I, Lan, Keng‐Li, Chen, Yi‐Wei, Kang, Yu‐Mei, Chou, Lin‐Shan, and Hu, Yu‐Wen
- Subjects
- *
BIOLOGICAL models , *PHARMACEUTICAL arithmetic , *RESEARCH funding , *STATISTICAL sampling , *RADIOSURGERY , *TREATMENT effectiveness , *DESCRIPTIVE statistics , *MANN Whitney U Test , *LUNGS , *LUNG tumors , *RADIATION doses , *COMPARATIVE studies - Abstract
Background: Limited literature exists on the feasibility and effectiveness of integrating stereotactic ablative radiotherapy (SABR) techniques with hyperfractionated regimens for patients with lung cancer. This study aims to assess whether the SABR technique with hyperfractionation can potentially reduce lung toxicity. Methods: We utilized the linear‐quadratic model to find the optimal fraction to maximize the tumor biological equivalent dose (BED) to normal‐tissue BED ratio. Validation was performed by comparing the SABR plans with 50 Gy/5 fractions and hyperfractionationed plans with 88.8 Gy/74 fractions with the same tumor BED and planning criteria for 10 patients with early‐stage lung cancer. Mean lung BED, Lyman–Kutcher–Burman (LKB) normal tissue complication probability (NTCP), critical volume (CV) criteria (volume below BED of 22.92 and 25.65 Gy, and mean BED for lowest 1000 and 1500 cc) and the percentage of the lung receiving 20Gy or more (V20) were compared using the Wilcoxon signed‐rank test. Results: The transition point occurs when the tumor‐to‐normal tissue ratio (TNR) of the physical dose equals the TNR of α/β in the BED dose‐volume histogram of the lung. Compared with the hypofractionated regimen, the hyperfractionated regimen is superior in the dose range above but inferior below the transition point. The hyperfractionated regimen showed a lower mean lung BED (6.40 Gy vs. 7.73 Gy) and NTCP (3.50% vs. 4.21%), with inferior results concerning CV criteria and higher V20 (7.37% vs. 7.03%) in comparison with the hypofractionated regimen (p < 0.01 for all). Conclusions: The hyperfractionated regimen has an advantage in the high‐dose region of the lung but a disadvantage in the low‐dose region. Further research is needed to determine the superiority between hypo‐ and hyperfractionation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Stereotactic radiosurgery for facial nerve hemangioma: Case report and systematic review.
- Author
-
Park, David J., Hori, Yusuke S., Nernekli, Kerem, Persad, Amit R., Tayag, Armine, Ustrzynski, Louisa, Emrich, Sara C., Hancock, Steven L., and Chang, Steven D.
- Abstract
• Facial nerve hemangiomas are rare tumors that can cause facial nerve dysfunction. • The optimal approach for treating FNHs remains uncertain due to their rarity. • This case demonstrates the feasibility of SRS as a standalone treatment. Facial nerve hemangiomas (FNHs) are rare tumors that primarily occur near the geniculate ganglion in the temporal bone. Despite their rarity, they can cause significant facial nerve dysfunction. The optimal management approach for FNHs remains uncertain, with surgery being the mainstay but subject to debate regarding the extent of resection and preservation of the facial nerve. Systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We queried the PubMed/Medline (accessed on 5 March 2024) electronic database using combinations of the following search terms and words text: "geniculate ganglion hemangioma", "ganglional hemangioma", "hemangioma of the facial nerve", "facial hemangioma", and "intratemporal hemangioma". We identified a total of 30 literatures (321 patients). The most common site involved for the facial nerve hemangioma was the geniculate ganglion area followed by internal auditory canal, tympanic segment, labyrinthine segment and mastoid involvement. All patients were treated with conservative management or surgery. We report a 48-year-old female patient with HB grade 2 facial palsy and hemifacial spasm underwent SRS using Cyberknife technology. The treatment targeted the FNH in the left internal acoustic canal near the geniculate ganglion. Six months post-treatment, clinical improvement was evident, and lesion control was confirmed in a follow-up brain MRI. The rarity of FNHs contributes to the lack of consensus on optimal management. This illustrative case demonstrates the feasibility of SRS as a standalone treatment for FNHs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Neurosurgical applications of radiotherapy.
- Author
-
Soldá, Francesca, Tancu, Cornel, Kitchen, Neil, and Fersht, Naomi
- Abstract
The term 'radiosurgery' (RS) indicates a high precision localized technique of irradiation used as an alternative to surgical excision in patients with malignant or benign conditions, both in the brain and in the body. Brain RS has been historically identified with 'stereotactic radiotherapy'. The term refers to the long-established neurosurgical technique of localizing the position of a lesion in the brain by using a system of external 3D co-ordinates coupled with rigid head immobilization device (often fixed to the skull). A high dose of radiation is delivered to the target stereotactically identified and a safe and accurate treatment is achieved, minimizing the dose of radiation to the surrounding brain. While for some techniques the traditional stereotactic localization has been replaced by the integration of modern imaging with non-invasive accurate immobilization, the term 'stereotactic' is still maintained in the clinical practice. Over the past 30 years, the implementation of powerful diagnostic imaging devices and of new radiotherapy equipment has contributed to the large diffusion of brain RS. RS plays an important role in the management of brain tumours, vascular and functional brain lesions and the expertise of the multidisciplinary treating team (clinical oncologists, neurosurgeons, neuro-radiologists and medical physics) contributes to the treatment success rate. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Long-term outcomes of central neurocytoma – an institutional experience.
- Author
-
Yang, Yufan, Wadhwani, Nitin, Shimomura, Aoi, Zheng, Shuhua, Chandler, James, Lesniak, Maciej S., Tate, Matthew C., Sonabend, Adam M., Kalapurakal, John, Horbinski, Craig, Lukas, Rimas, Stupp, Roger, Kumthekar, Priya, and Sachdev, Sean
- Abstract
Introduction: Central Neurocytoma (CN) is a rare, WHO grade 2 brain tumor that predominantly affects young adults. Gross total resection (GTR) is often curative for CNs, but the optimal treatment paradigm including incorporation of RT, following subtotal resection (STR) and for scarcer pediatric cases has yet to be established. Methods: Patients between 2001 and 2021 with a pathologic diagnosis of CN were reviewed. Demographic, treatment, and tumor characteristics were recorded. Recurrence free survival (RFS) and overall survival (OS) were calculated according to the Kaplan Meier-method. Post-RT tumor volumetric regression analysis was performed. Results: Seventeen adults (≥ 18 years old) and 5 children (< 18 years old) met the criteria for data analysis (n = 22). With a median follow-up of 6.9 years, there was no tumor-related mortality. Patients who received STR and/or had atypical tumors (using a cut-off of Ki-67 > 4%) experienced decreased RFS compared to those who received GTR and/or were without atypical tumors. RFS at 5 years for typical CNs was 67% compared to 22% for atypical CNs. Every pediatric tumor was atypical and 3/5 recurred within 5 years. Salvage RT following tumor recurrence led to no further recurrences within the timeframe of continued follow-up; volumetric analysis for 3 recurrent tumors revealed an approximately 80% reduction in tumor size. Conclusion: We provide encouraging evidence that CNs treated with GTR or with RT after tumor recurrence demonstrate good long-term tumor control. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review.
- Author
-
Zarba, Martin, Fujiwara, Ryo, Yuasa, Takeshi, Koga, Fumitaka, Heng, Daniel Y C, and Takemura, Kosuke
- Subjects
RENAL cell carcinoma ,STEREOTACTIC radiotherapy ,METASTASIS ,PATIENT selection ,METASTASECTOMY ,COMBINED modality therapy - Abstract
Systemic and local therapies for patients with metastatic renal cell carcinoma (mRCC) are often challenging despite the evolution of multimodal cancer therapies in the last decade. In this review, we will focus on recent multidisciplinary approaches for patients with mRCC. Systemic therapies for patients with mRCC have been garnering attention particularly after the approval of immuno-oncology (IO) agents, including anti-programmed death 1/programmed death-ligand 1. IO combinations have significantly prolonged overall survival in patients with mRCC in the first-line setting. Regarding local therapies, cytoreductive nephrectomy (CN) has become less common in the post-Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques (CARMENA) trial era, even though CN may still benefit selected patients with mRCC. In addition, metastasis-directed local therapies, namely metastasectomy or stereotactic radiotherapy, particularly for oligo-metastatic lesions or brain metastases, may have a prognostic impact. Several ablative techniques are also evolving while maintaining high local control rates with acceptable safety. Multimodal cancer therapies are essential for conquering complex cases of mRCC. Modern systemic therapies including IO-based combination therapy as well as local therapies including CN, metastasectomy, stereotactic radiotherapy, and ablative techniques appear to improve oncologic outcomes of patients with mRCC, although appropriate patient selection is indispensable. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. From data to practice: brain meningioma treatment in elderly patients – a survey of the Italian Society of Neurosurgery (SINch®) and systematic review and meta-analysis.
- Author
-
Ius, Tamara, Raffa, Giovanni, Aiudi, Denis, Panciani, Pier Paolo, Della Pepa, Giuseppe Maria, Pessina, Federico, Solari, Domenico, Somma, Teresa, Angileri, Filippo Flavio, Nichelatti, Michele, Cappabianca, Paolo, Esposito, Vincenzo, Fornari, Maurizio, Iacopino, Domenico Gerardo, Olivi, Alessandro, Sala, Francesco, Cavallo, Luigi Maria, La Camera, Alessandro, Barbagallo, Giuseppe, and Barbanera, Andrea
- Abstract
The management of meningioma in elderly patients (MEP) presents a complex and evolving challenge. Data available offer conflicting information on treatment options and complications. This survey aimed to examine the current approach to MEP, comparing the national profile to data in the current literature. A survey addressing the treatments options and management of meningioma in elderly was designed on behalf of SINch® (Società Italiana di Neurochirurgia) and sent via email to all Chiefs of Neurosurgical Departments. The survey remained open for responses from May 5th, 2022, until November 21st, 2022. A search of the literature published between January 2000 and March 2023, in accordance to PRISMA guidelines, was included. A total of 51 Neurosurgical centers participated in the survey. The caseload profile of each center influences the choice of treatment selection (Stereotactic Radiosurgery versus open surgery) (p = 0.01) and the consolidated practice of discussing cases within a multidisciplinary group (p = 0.02). The pooled meta-analysis demonstrated a significant increased risk in the elderly group for permanent deficits (p < 0.00001), postoperative infections (p = 0.0004) and hemorrhage (p = 0.0001), perioperative mortality (p < 0.00001), and medical complications (p < 0.00001) as compared to the young population. This study presents the initial comprehensive analysis of the existing trends in the surgical management of MEP in Italy. The significant variation in practices primarily stems from the absence of standardized guidelines. While most centers have adopted an integrated approach, there is a need to promote a multidisciplinary care model. Prospective studies are needed to gather robust evidence in this clinical setting. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Initial Age and Performans Status: Predicators for Re-Irradiation Ability in Patients with Relapsed Brain Metastasis after Initial Stereotactic Radiotherapy.
- Author
-
Chambrelant, Isabelle, Kuntz, Laure, Le Fèvre, Clara, Jarnet, Delphine, Jacob, Julian, and Noël, Georges
- Subjects
- *
RISK assessment , *BRAIN , *KARNOFSKY Performance Status , *RADIOSURGERY , *AGE distribution , *FUNCTIONAL status , *TREATMENT effectiveness , *RETROSPECTIVE studies , *METASTASIS , *DISEASE relapse , *OVERALL survival - Abstract
Simple Summary: Brain metastases (BMs) are common in cancer patients, and stereotactic radiation therapy (SRT) is a preferred treatment. This retrospective study analyzed patients treated with SRT for a single BM and compared two subgroups: "Cohort 1" (no cerebral re-irradiation) and "Cohort 2" (received subsequent SRT sessions for recurrence). Patients treated with SRT for a single BM between January 2010 and June 2020 were included. Cohort 1 had 152 patients, and Cohort 2 had 46 patients. Cohort 2 had younger patients with higher Karnofsky performance status (KPS). Median overall survival was longer in Cohort 2 (21.8 months) compared to Cohort 1 (6.1 months). Recurrence rates were higher in Cohort 2 (p < 0.001), likely due to patient selection and longer survival. Age and KPS were predictive of survival, especially for patients under 65 with KPS > 80. Age and KPS predict better survival in patients with BMs. Background: Brain metastases (BMs) frequently occur in cancer patients, and stereotactic radiation therapy (SRT) is a preferred treatment option. In this retrospective study, we analyzed patients treated by SRT for a single BM during their first SRT session and we compared two subgroups: "Cohort 1" with patients did not undergo cerebral re-irradiation and "Cohort 2" with patients received at least one subsequent SRT session for cerebral recurrence. Methods: We included patients who received SRT for a single BM between January 2010 and June 2020. Cohort 1 comprised 152 patients, and Cohort 2 had 46 patients. Results: Cohort 2 exhibited younger patients with higher Karnofsky performance status (KPS). Median overall survival was considerably longer in Cohort 2 (21.8 months) compared to Cohort 1 (6.1 months). Local and cerebral recurrence rates were significantly higher in Cohort 2 (p < 0.001), attributed to patient selection and longer survival. The combined score of age and KPS proved to be a predictive factor for survival, with patients under 65 years of age and KPS > 80 showing the best survival rates in the overall population. Conclusion: This retrospective study highlights that the combined score of age and KPS can predict better survival, especially for patients under 65 years with a KPS score above 80. Further research involving larger and more diverse populations is essential to validate and expand upon these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Baseline Blood CD8 + T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer.
- Author
-
Kievit, Hanneke, Muntinghe-Wagenaar, M. Benthe, Abdulahad, Wayel H., Rutgers, Abraham, Hijmering-Kappelle, Lucie B. M., Hiddinga, Birgitta I., Ubbels, J. Fred, Wijsman, Robin, van der Leij, Marcel J., Bijzet, Johan, Groen, Harry J. M., Kerstjens, Huib A. M., van der Wekken, Anthonie J., Kroesen, Bart-Jan, and Hiltermann, T. Jeroen N.
- Subjects
- *
FLOW cytometry , *T cells , *RESEARCH funding , *IMMUNOTHERAPY , *RADIOSURGERY , *TUMOR markers , *MANN Whitney U Test , *DESCRIPTIVE statistics , *IMMUNE checkpoint inhibitors , *RESEARCH , *LUNG cancer , *PROGRESSION-free survival , *CYTOKINES , *COMPARATIVE studies , *INTERLEUKINS , *TUMOR necrosis factors ,BODY fluid examination - Abstract
Simple Summary: Cancer may be recognized by the immune system. For patients with non-small-cell lung cancer (NSCLC), immune checkpoint inhibitors (ICI) are a first-line treatment in most patients. However, most of these patients do not respond to ICI, implying that the treatment is ineffective, where it may have relevant side effects. Currently, there is no solid biomarker to predict response to ICI. Thus, there is an urgent need for a new biomarker to predict this response, preferably via minimally invasive techniques. We tested the potency of T cells to be activated ex vivo in the peripheral blood of patients with advanced NSCLC. We found an increased ability to activate CD8+ T cells and produce intracellular IL-2 in peripheral CD8+ T cells in patients that respond to ICI compared to non-responders and healthy controls before the start of ICI. The potency of peripheral T cells to be activated before treatment seems a promising biomarker. Background: Tumor-infiltrating immune cells have been correlated with prognosis for patients treated with immune checkpoint inhibitor (ICI) treatment of various cancers. However, no robust biomarker has been described to predict treatment response yet. We hypothesized that the activation potency of circulating T cells may predict response to ICI treatment. Methods: An exploratory analysis was conducted to investigate the association between the response to immune checkpoint inhibition (ICI) combined with stereotactic radiotherapy (SBRT) and the potency of circulating T cells to be activated. Blood-derived lymphocytes from 14 patients were stimulated ex vivo with, among others, Staphylococcal enterotoxin B (SEB) and compared to healthy controls (HCs). Patients were grouped into responders (>median progression free survival (PFS)) and non-responders (
- Published
- 2024
- Full Text
- View/download PDF
40. Stereotactic radiosurgery for intraventricular meningioma: a systematic review and meta-analysis.
- Author
-
Khaboushan, Alireza Soltani, Ohadi, Mohammad Amin Dabbagh, Amani, Hanieh, Dashtkoohi, Mohammad, Iranmehr, Arad, and Sheehan, Jason P.
- Subjects
- *
STEREOTACTIC radiosurgery , *MENINGIOMA , *INTRACRANIAL tumors , *LOG-rank test , *PROGRESSION-free survival , *CONSERVATIVE treatment , *INTRAVENTRICULAR hemorrhage - Abstract
Background: Intraventricular meningioma (IVM) is a rare subtype of intracranial meningioma, accounting for 9.8 to 14% of all intraventricular tumors. Currently, there is no clear consensus on which patients with IVM should receive conservative treatment, surgery, or stereotactic radiosurgery (SRS). This research aims to analyze the outcomes, including survival and recurrence rates of patients who undergo SRS for IVM as a primary or adjuvant treatment. Methods: A systematic search was conducted in Scopus, Web of Science, PubMed, and Embase till June 5th 2023. Screening and data extraction were performed by two independent authors. Random-effect meta-analysis was performed to determine the tumor control proportion of IVM cases treated with SRS. Individual patient data (IPD) meta-analysis was performed for the progression-free survival (PFS) of the patients in the follow-up time. All analyses were performed using the R programming language. Results: Out of the overall 132 records, 14 were included in our study, of which only 7 had enough data for the meta-analysis. The tumor control proportion was 0.92 (95% CI, 0.69–0.98) in patients who underwent SRS for primary IVM. The overall tumor control in both primary and adjuvant cases was 0.87 (95% CI, 0.34–0.99). the heterogeneity was not significant in both meta-analyses (P = 0.73 and P = 0.92, respectively). Post-SRS perifocal edema occurred in 16 out of 71 cases (0.16; 95% CI, 0.03–0.56), with no significant heterogeneity (P = 0.32). IPD meta-analysis showed a PFS of 94.70% in a 2-year follow-up. Log-rank test showed better PFS in primary SRS compared to adjuvant SRS (P < 0.01). Conclusions: According to this study, patients with IVM can achieve high rates of tumor control with a low risk of complications when treated with SRS, regardless of whether they have received prior treatment. Although SRS could be a promising first-line treatment option for asymptomatic IVM, its efficacy in symptomatic patients and its comparison with resection require further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Gamma knife radio surgery for cerebral arteriovenous malformation (AVM) in children: a systematic review and meta-analysis of clinical outcomes.
- Author
-
Florez-Perdomo, William Andrés, Reyes Bello, Juan Sebastián, Moscote Salazar, Luis Rafael, Agrawal, Amit, Janjua, Tariq, Chavda, Vishal, García-Ballestas, Ezequiel, and Abdulla, Ebtesam
- Subjects
- *
CEREBRAL arteriovenous malformations , *RADIOSURGERY , *TREATMENT effectiveness , *INTRACRANIAL hemorrhage , *PEDIATRIC therapy , *CHILD patients - Abstract
This article aims to evaluate the safety and effectiveness of Gamma Knife radiosurgery as a treatment modality for pediatric cerebral arteriovenous malformations (AVMs) by assessing mortality rates, the rate of complete AVM obliteration, and the incidence of complications while exploring potential risk factors. A comprehensive search was conducted through multiple databases to identify relevant studies, including randomized controlled trials and observational studies. The studies were assessed for risk of bias using the ROBINS-I tool and methodological quality with the Newcastle–Ottawa Scale. Data on mortality, AVM obliteration rates, and complications were systematically extracted. Pooled rate analysis was performed to assess outcomes, and heterogeneity was evaluated. The analysis included 21 studies involving 2142 pediatric patients with cerebral AVMs. A low mortality rate of 0.75% (95% CI 0.09% to 2.71%) and a high rate of complete obliteration of AVMs was observed, with a rate of 71.64% (95% CI 65.716% to 77.211%). Complications, including new neurological deficits, post-radiosurgery intracranial hemorrhage, and other complications (such as seizures and radiation-related issues), were relatively low, with rates of 2.57%, 2.463%, and 4.784%, respectively. Gamma Knife radiosurgery demonstrates its potential as a safe and effective treatment option for pediatric cerebral AVMs. The low mortality rate and high rate of AVM obliteration suggest that this approach offers significant benefits. While some complications were observed, they were generally non-severe. However, further high-quality studies with extended follow-up periods are needed to better understand long-term efficacy and safety. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. A Potential Risk of Radiation-Induced Cavernous Malformations Following Adjuvant Gamma Knife Radiosurgery for Mesial Temporal Lobe Epilepsy.
- Author
-
Kim, Junhyung, Byun, Joonho, Lee, Do Heui, and Hong, Seok Ho
- Subjects
- *
RADIOSURGERY , *TEMPORAL lobe epilepsy , *EPILEPSY , *HUMAN abnormalities , *TEMPORAL lobectomy , *HIPPOCAMPAL sclerosis - Abstract
Objective: Several clinical studies have explored the feasibility and efficacy of radiosurgical treatment for mesial temporal lobe epilepsy, but the long-term safety of this treatment has not been fully characterized. This study aims to report and describe radiation-induced cavernous malformation as a delayed complication of radiosurgery in epilepsy patients. Methods: The series includes 20 patients with mesial temporal lobe epilepsy who underwent Gamma Knife radiosurgery (GKRS). The majority received a prescribed isodose of 24 Gy as an adjuvant treatment after anterior temporal lobectomy. Results: In this series, we identified radiation-induced cavernous malformation in three patients, resulting in a cumulative incidence of 18.4% (95% confidence interval, 6.3% to 47.0%) at an 8-year follow-up. These late sequelae of vascular malformation occurred between 6.9 and 7.6 years after GKRS, manifesting later than other delayed radiation-induced changes, such as radiation necrosis. Neurological symptoms attributed to intracranial hypertension were present in those three cases involving cavernous malformation. Of these, two cases, which initially exhibited an insufficient response to radiosurgery, ultimately demonstrated seizure remission following the successful microsurgical resection of the cavernous malformation. Conclusion: All things considered, the development of radiation-induced cavernous malformation is not uncommon in this population and should be acknowledged as a potential long-term complication. Microsurgical resection of cavernous malformation can be preferentially considered in cases where the initial seizure outcome after GKRS is unsatisfactory. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Feasibility of Gamma Knife Radiosurgery for Brain Arteriovenous Malformations According to Nidus Type.
- Author
-
Koo, Ja Ho, Hwang, Eui Hyun, Song, Ji Hye, and Lim, Yong Cheol
- Subjects
- *
RADIOSURGERY , *CEREBRAL arteriovenous malformations , *STEREOTACTIC radiosurgery , *DIGITAL subtraction angiography , *MAGNETIC resonance imaging , *ARTERIOVENOUS malformation , *PATIENT safety - Abstract
Objective: Gamma Knife radiosurgery (GKRS) is an effective and noninvasive treatment for high-risk arteriovenous malformations (AVMs). Since differences in GKRS outcomes by nidus type are unknown, this study evaluated GKRS feasibility and safety in patients with brain AVMs. Methods: This single-center retrospective study included patients with AVM who underwent GKRS between 2008 and 2021. Patients were divided into compact- and diffuse-type groups according to nidus characteristics. We excluded patients who performed GKRS and did not follow-up evaluation with magnetic resonance imaging or digital subtraction angiography within 36 months from the study. We used univariate and multivariate analyses to characterize associations of nidus type with obliteration rate and GKRS-related complications. Results: We enrolled 154 patients (mean age, 32.14±17.17 years; mean post-GKRS follow-up, 52.10±33.67 months) of whom 131 (85.1%) had compact- and 23 (14.9%) diffuse-type nidus AVMs. Of all AVMs, 89 (57.8%) were unruptured, and 65 (42.2%) had ruptured. The mean Spetzler-Martin AVM grades were 2.03±0.95 and 3.39±1.23 for the compact- and diffuse-type groups, respectively (p<0.001). During the follow-up period, AVM-related hemorrhages occurred in four individuals (2.6%), three of whom had compact nidi. Substantial radiation-induced changes and cyst formation were observed in 21 (13.6%) and one patient (0.6%), respectively. The AVM complete obliteration rate was 46.1% across both groups. Post-GKRS complication and complete obliteration rates were not significantly different between nidus types. For diffuse-type nidus AVMs, larger AVM size and volume (p<0.001), lower radiation dose (p<0.001), eloquent area location (p=0.015), and higher Spetzler-Martin grade (p<0.001) were observed. Conclusion: GKRS is a safe and feasible treatment for brain AVMs characterized by both diffuse- and compact-type nidi. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Hearing Function after CyberKnife for Vestibular Schwannoma: A Systematic Review.
- Author
-
Tavares, Matheus Pedrosa and Bahmad Jr, Fayez
- Subjects
- *
ACOUSTIC neuroma , *NEUROFIBROMATOSIS 2 , *RANDOM effects model - Abstract
Introduction CyberKnife (CK) radiosurgery is a treatment strategy for vestibular schwannoma (VS). Objectives To evaluate hearing preservation (HP) after CK for VS. Data Synthesis The study was conducted following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, and it was registered at the International Prospective Register of Systematic Reviews (PROSPERO, under number CRD42021250300). The inclusion criteria were based on the population, intervention, comparison, outcome, timing and study design (PICOTS) strategy: population – patients with VS; intervention – CK; Comparison – none; Outcome – serviceable HP defined by Gardner and Robertson as grades I or II, or by the American Academy of Otolaryngology and Head and Neck Surgery as classes A or B; timing – mean follow-up longer than 1 year; and study design – retrospective or prospective studies. The exclusion criteria were: studies not published in English; studies published before January 2000 and after October 2021; and studies only including patients with neurofibromatosis type 2 or submitted to a previous treatment. The PubMed/MEDLINE, EMBASE, Web of Science, Cochrane Library, LILACS, and IBECS databases were used and last searched on October 27th, 2021. Statistical heterogeneity was assessed using I2 statistics. The appraisal checklist was used to assess the risk of bias in the included studies. A total of 222 studies were analyzed, and 13 were included in the synthesis, which represents 493 participants with serviceable hearing before intervention. The mean HP rate after CK using a random effects model was of 68% (95% confidence interval [95%CI]: 59–76%) at a mean follow-up of 42.96 months. Conclusion The longer follow-up period was associated with a lower HP rate after CK radiosurgery for VS in the qualitative synthesis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Radiosurgically Treated Recurrent Cerebellar Hemangioblastoma: A Case Report and Literature Review.
- Author
-
Fabi, François, Chamberland, Ève, D'Astous, Myreille, Michaud, Karine, Côté, Martin, and Thibault, Isabelle
- Subjects
- *
LITERATURE reviews , *STEREOTACTIC radiosurgery , *TUMOR growth , *SURGICAL excision ,CENTRAL nervous system tumors - Abstract
Background: Cystic, sporadic hemangioblastomas (HBLs) represent a unique, therapeutically challenging subset of central nervous system tumors, mainly due to their unpredictable growth patterns and potential for symptomatic progression. This study aims to explore the complexities surrounding the diagnosis, treatment, and long-term management of these lesions. Methods: A comprehensive literature review was performed, and a detailed case study of a 56-year-old patient with a cystic, sporadic cerebellar HBL was produced. Results: The case highlights the multiphasic growth pattern typical of cystic, sporadic HBLs, characterized by periods of dormancy and subsequent rapid expansion. An initial surgical intervention offered temporary control. Tumor recurrence, mainly through cystic enlargement, was treated by SRS. A subsequent recurrence, again caused by cystic growth, eventually led to the patient's death. The intricacies of treatment modalities, focusing on the transition from surgical resection to stereotactic radiosurgery (SRS) upon recurrence, are discussed. Parameters indicating impending tumor growth, coupled with symptomatic advances, are also explored. Conclusions: The management of cystic, sporadic cerebellar HBLs requires a strategic approach that can be informed by radiological characteristics and tumoral behavior. This study underscores the importance of a proactive, individualized management plan and suggests guidelines that could inform clinical decision making. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Total Neoadjuvant Therapy in Localized Pancreatic Cancer: Is More Better?
- Author
-
Saúde-Conde, Rita, El Ghali, Benjelloun, Navez, Julie, Bouchart, Christelle, and Van Laethem, Jean-Luc
- Subjects
- *
RADIOTHERAPY , *SURVIVAL rate , *CHEMORADIOTHERAPY , *RADIOSURGERY , *TREATMENT effectiveness , *PANCREATIC tumors , *CANCER chemotherapy , *COMBINED modality therapy , *QUALITY assurance , *OVERALL survival - Abstract
Simple Summary: Pancreatic cancer is challenging to treat due to late diagnosis and limited options. Surgery, the main treatment, often leads to poor long-term outcomes, prompting exploration of alternative approaches like neoadjuvant therapy (NAT) and total neoadjuvant therapy (TNT). While NAT aims to improve surgical success and overall survival, there is room for enhancement, leading to consideration of neoadjuvant strategies combining full-dose chemotherapy and radiotherapy in TNT. TNT, integrating chemotherapy and radiotherapy before surgery, could increase the likelihood of successful surgery and cure for locally advanced cases. This article explores different TNT strategies, categorized based on radiotherapy techniques, offering a thorough analysis of their effectiveness in borderline resectable and locally advanced pancreatic cancer. The central question remains: does more treatment before surgery always yield better results? Pancreatic ductal adenocarcinoma (PDAC) poses a significant challenge in oncology due to its advanced stage upon diagnosis and limited treatment options. Surgical resection, the primary curative approach, often results in poor long-term survival rates, leading to the exploration of alternative strategies like neoadjuvant therapy (NAT) and total neoadjuvant therapy (TNT). While NAT aims to enhance resectability and overall survival, there appears to be potential for improvement, prompting consideration of alternative neoadjuvant strategies integrating full-dose chemotherapy (CT) and radiotherapy (RT) in TNT approaches. TNT integrates chemotherapy and radiotherapy prior to surgery, potentially improving margin-negative resection rates and enabling curative resection for locally advanced cases. The lingering question: is more always better? This article categorizes TNT strategies into six main groups based on radiotherapy (RT) techniques: (1) conventional chemoradiotherapy (CRT), (2) the Dutch PREOPANC approach, (3) hypofractionated ablative intensity-modulated radiotherapy (HFA-IMRT), and stereotactic body radiotherapy (SBRT) techniques, which further divide into (4) non-ablative SBRT, (5) nearly ablative SBRT, and (6) adaptive ablative SBRT. A comprehensive analysis of the literature on TNT is provided for both borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC), with detailed sections for each. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer.
- Author
-
O'Donnell, Conor D. J., Naleid, Nikolas, Siripoon, Teerada, Zablonski, Kevin G., Storandt, Michael H., Selfridge, Jennifer E., Hallemeier, Christopher L., Conces, Madison L., Jethwa, Krishan R., Bajor, David L., Thiels, Cornelius A., Warner, Susanne G., Starlinger, Patrick P., Atwell, Thomas D., Mitchell, Jessica L., Mahipal, Amit, and Jin, Zhaohui
- Subjects
- *
RISK assessment , *CANCER relapse , *DATA analysis , *ABLATION techniques , *GENETIC markers , *COLORECTAL cancer , *TUMOR markers , *RETROSPECTIVE studies , *RADIOSURGERY , *METASTASIS , *KAPLAN-Meier estimator , *LOG-rank test , *CANCER chemotherapy , *NUCLEIC acids , *RESEARCH , *EXTRACELLULAR space , *PROGRESSION-free survival , *TUMOR antigens , *HEPATECTOMY , *GENETIC testing , *PATIENT aftercare , *DISEASE risk factors - Abstract
Simple Summary: Colorectal cancer is a major cause of cancer death, often due to metastasis. For patients with limited spread, treatments to remove all cancerous lesions can extend life or even cure the disease. However, predicting who benefits most from further treatment is challenging. This study used tumor-informed circulating tumor DNA (ctDNA) testing to detect minimal residual disease (MRD) after locoregional therapy for metastatic colorectal cancer. The results showed that positive ctDNA results after curative-intent treatment predict poor prognosis better than traditional tests. Those with negative ctDNA had over three times longer survival without recurrence compared to those with positive ctDNA. In this group of patients, the majority of whom had received prior chemotherapy, receiving more of the same chemotherapy did not seem to delay cancer recurrence. These preliminary results set the stage for future prospective trials which may examine the value of ctDNA-guided patient management for those with colorectal cancer and limited metastatic disease. (1) Background: Local therapies offer a potentially curative approach for patients with oligometastatic colorectal cancer (CRC). An evidence-based consensus recommendation for systemic therapy following definitive locoregional therapy is lacking. Tumor-informed circulating tumor DNA (ctDNA) might provide information to help guide management in this setting. (2) Methods: A multi-institutional retrospective study was conducted, including patients with CRC that underwent curative-intent locoregional therapy to an isolated site of metastatic disease, followed by tumor-informed ctDNA assessment. The Kaplan–Meier method and log-rank tests were used to compare disease-free survival based on ctDNA results. ctDNA test performance was compared to carcinoembryonic antigen (CEA) test results using McNemar's test. (3) Results: Our study cohort consisted of 87 patients treated with locoregional interventions who underwent ctDNA testing. The initial ctDNA test post-intervention was positive in 28 patients and negative in 59 patients. The median follow-up time was 14.0 months. Detectable ctDNA post-intervention was significantly associated with early disease recurrence, with a median disease-free survival (DFS) of 6.63 months compared to 21.30 months in ctDNA-negative patients (p < 0.001). ctDNA detected a numerically higher proportion of recurrences than CEA (p < 0.097). Post-intervention systemic therapy was not associated with improved DFS (p = 0.745). (4) Conclusions: ctDNA results are prognostically important in oligometastatic CRC, and further prospective studies are urgently needed to define its role in guiding clinical decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Optimizing Choice of Skin Surrogates for Surface-Guided Stereotactic Body Radiotherapy of Lung Lesions Using Four-Dimensional Computed Tomography.
- Author
-
Leipold, Vanda, Alerić, Ivana, Mlinarić, Mihaela, Kosmina, Domagoj, Stanić, Fran, Kasabašić, Mladen, Štimac, Damir, Kaučić, Hrvoje, Ursi, Giovanni, Schwarz, Karla, Nikolić, Igor, Klapan, Denis, and Schwarz, Dragan
- Subjects
- *
STATISTICAL correlation , *PEARSON correlation (Statistics) , *RADIOTHERAPY , *ADIPOSE tissues , *DATA analysis , *T-test (Statistics) , *COMPUTED tomography , *SEX distribution , *SAMPLE size (Statistics) , *RADIOSURGERY , *MANN Whitney U Test , *CHI-squared test , *DESCRIPTIVE statistics , *SKIN , *LUNG tumors , *RESEARCH , *FRIEDMAN test (Statistics) , *STATISTICS , *CONFIDENCE intervals , *RESPIRATORY mechanics , *RIB cage - Abstract
Simple Summary: Surface tracking based on optical cameras is often used to reduce the imaging dose while maintaining precision during stereotactic ablative body radiotherapy. A region of interest (ROI) on a patient's skin is selected and monitored using harmless visible light in real time. Relying on the correlation between the skin and lesion respiratory motion, this region of interest is used as a surrogate for the tumor respiratory motion. In this study, the thoracic and abdominal skin region is segmented into nine smaller regions. For each of them, the respiratory motion magnitude and its correlation with a small structure in the lower lung (representing a lung lesion) are measured. Using the data provided by this study, a clinician can make an informed decision about which ROI to track when treating lower lung lobe lesions. Image-guided radiotherapy supported by surface guidance can help to track lower lung lesions' respiratory motion while reducing a patient's exposure to ionizing radiation. However, it is not always clear how the skin's respiratory motion magnitude and its correlation with the lung lesion's respiratory motion vary between different skin regions of interest (ROI). Four-dimensional computed tomography (4DCT) images provide information on both the skin and lung respiratory motion and are routinely acquired for the purpose of treatment planning in our institution. An analysis of 4DCT images for 57 patients treated in our institution has been conducted to provide information on the respiratory motion magnitudes of nine skin ROIs of the torso, a tracking structure (TS) representing a lower lung lobe lesion, as well as the respiratory motion correlations between the nine ROIs and the TS. The effects of gender and the adipose tissue volume and distribution on these correlations and magnitudes have been analyzed. Significant differences between the ROIs in both the respiratory motion magnitudes and their correlations with the TS have been detected. An overall negative correlation between the ROI respiratory magnitudes and the adipose tissue has been detected for ROIs with rib cage support. A weak to moderate negative correlation between the adipose tissue volume and ROI-to-TS respiratory correlations has been detected for upper thorax ROIs. The respiratory magnitudes in regions without rib support tend to be larger for men than for women, but no differences in the ROI-to-TS correlation between sexes have been detected. The described findings should be considered when choosing skin surrogates for lower lung lesion motion management. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Comparative Analysis of Stereotactic Radiation Therapy and Conventional Radiation Therapy in Cancer Pain Control: A Systematic Review and Meta-Analysis.
- Author
-
Tariq, U.B., Naseer Khan, M.A., Barkha, F.N.U., Sagar, R.S., Suchwani, D., Abdelsamad, O., Bhatt, D., Shakil, G., Rasool, S., Subedi, S., Versha, F.N.U., Bhatia, V., Kumar, S., and Khatri, M.
- Subjects
- *
STATISTICAL models , *RISK assessment , *RADIOTHERAPY , *RADIOSURGERY , *TREATMENT effectiveness , *META-analysis , *CANCER patients , *RELATIVE medical risk , *DESCRIPTIVE statistics , *COMPRESSION fractures , *VERTEBRAL fractures , *CANCER pain , *BONE metastasis , *SYSTEMATIC reviews , *MEDLINE , *PAIN management , *MEDICAL databases , *ONLINE information services , *CONFIDENCE intervals , *RADIODERMATITIS , *CANCER fatigue , *DEGLUTITION disorders , *ESOPHAGUS diseases , *NAUSEA , *PATIENT aftercare , *DISEASE progression , *DISEASE incidence - Abstract
Approximately 55% of patients diagnosed with primary or metastatic cancer endure pain directly attributable to the disease. Consequently, it becomes imperative to address pain management through a comparative analysis of stereotactic radiotherapy (SRT) and conventional radiation therapy (CRT), especially in light of the less efficacious improvement achieved solely through pharmacological interventions. A systematic exploration was undertaken on PubMed, the Cochrane Library, and Elsevier's ScienceDirect databases to identify studies that compare Stereotactic Radiotherapy to Conventional radiation therapy for pain management in individuals with metastatic bone cancer. The analyses were executed utilizing the random-effects model. A cohort of 1152 participants with metastatic bone cancer was analyzed, demonstrating significantly higher complete pain relief in the Stereotactic Radiotherapy group during both early and late follow-up (RR: 1.61; 95% CI: 1.17, 2.23, p-value: 0.004; I2: 0%). Stereotactic Radiotherapy also showed a non-significant increase in the incidence of partial pain relief (RR: 1.07; 95% CI: 0.85, 1.34, p-value: 0.56; I2: 18%). Furthermore, Stereotactic Radiotherapy was associated with a significantly reduced risk of stationary pain throughout follow-up (RR: 0.61; 95%CI: 0.48, 0.76, p-value: <0.0001; I2: 0. The incidence of progressive pain was non-significantly reduced with Stereotactic Radiotherapy during both early and late follow-up (RR: 0.77; 95% CI: 0.50, 1.17, p-value: 0.22; I2: 0%). Secondary outcomes exhibited a non-significant trend favoring Stereotactic Radiotherapy for dysphagia, esophagitis, pain, and radiodermatitis, while a non-significant increase was observed for nausea, fatigue, and vertebral compression fracture. In summary, stereotactic radiation therapy (SRT) has improved in achieving complete pain relief while exhibiting a decreased probability of delivering stationary pain compared to conventional radiation therapy (CRT). Nevertheless, it is crucial in future research to address a noteworthy limitation, specifically, the risk of vertebral compression fracture. • SRT demonstrated higher rates of complete pain relief in early and late follow-ups. • Non-significant differences in partial pain relief incidence were seen with SRT. • SRT significantly reduced the risk of stationary pain throughout follow-up. • Non-significant differences in pain progression risk were observed with SRT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Performing a comprehensive radio-physical examination of the leksell gamma knife Icon treatment unit.
- Author
-
Natesan, Ponnusamy, Palaniappan, Senthil Manikandan, Bahadur, Sulthan Asath, Muthuvinayagam, Muthiah, Sadashiva, Nishanth, and Karthick, Nanda
- Subjects
IONIZATION chambers ,CORPORATE resolutions ,ABSORBED dose ,RADIOSURGERY ,COLLIMATORS ,STEREOTACTIC radiosurgery - Abstract
The Gamma Knife Icon unit is the latest radiosurgery equipment used for noninvasively treating intra-cranial diseases through Stereotactic radiosurgery treatment procedures. Performing radio-physical testing on the new Gamma Knife Icon unit before starting clinical procedures is essential to ensure its functionality. In line with the manufacturer's recommendations and the American Association of Physicists in Medicine (AAPM) formed Task Group 178 (TG-178), we conducted the vital radio physical tests for the newly installed Gamma Knife unit, including precision of beam alignment, measurement of Gamma Knife accuracy, Center Position measurements, off center position measurements, measurement of absorbed dose rate, and Relative Output factor measurement. We used high special resolution External Beam Therapy 3 (EBT3) GafChromic film and small volume ion chambers (Exradin A16, chamber volume 0.007 cc and PTW 0.125 cc) for the above mentioned tests. We also performed the source confirmation test with a 16 mm collimator. Our results are consistent with previous literature values and within international guidelines' acceptable measurement uncertainty tolerance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.